COVID: Research suggests AstraZeneca booster works against Omicron New Health

The findings of the study, which have not yet been reviewed by peers, are consistent with those of Pfizer-BioNTech and Moderna.

AstraZeneca said a third dose of its COVID-19 vaccine had “significantly” increased antibody levels. Omikron a variant of coronavirus, citing data from a new laboratory study.

The research findings, to be published in a peer-reviewed medical journal, are in line with rivals Pfizer-BioNTech and Moderna, who also found that a third dose of their shots works against Omicron.

AstraZeneca’s Vaxzevria vaccine study showed that after three doses of the vaccine, the levels of neutralization against Omicron were similar to those against the Delta variant of the virus after two doses.

Levels of neutralizing antibodies were also higher than those of people who had previously been infected with the booster owner and recovered naturally.

The company said the researchers at Oxford University were independent of those who worked on developing the vaccine with AstraZeneca last year.

“As we better understand Omicron, we believe that the T-cell response provides lasting protection against serious illness and hospitalization,” said Mene Pangalos, head of R&D at AstraZeneca’s biopharmaceuticals, referring to a critical component of the immune system that responds. to fight infection.

The threat of the highly transmissible Omicron variant is high during the December holiday season, forcing several governments to open new borders and require citizens to be vaccinated.

However, separate United Kingdom research has suggested that Omicron infections can lead to hospitalization compared to the Delta variant.

Boosters limit the spread of Omicron

Oxford researchers looked at blood samples taken from people infected with COVID-19; vaccine with two doses plus a booster; and those who reported a previous infection.

“It is very gratifying to see that today’s vaccines have the potential to protect against Omicron after a third booster dose,” said John Bell Oxford University professor, one of the research researchers.

“These results support the use of third-party promoters as part of vaccination strategies, especially to limit the spread of worrying variants, including Omicron.”

WHO warning

On Wednesday, the World Health Organization issued a stern warning to rich countries, arguing that they are moving away from poor nations to valuable possessions and pushing them to exacerbate the virus crisis.

“It is likely that the COVID-19 pandemic will be extended by diverting supplies to countries with high vaccination coverage, rather than ending it, giving more opportunities to spread and mutate the virus,” said WHO Director-General Tedros Adhanom. Ghebreyesus warned.

Recent data suggest that Omicron does not cause more serious disease than its predecessors, including Delta, but that the number of infections threatens to overwhelm the health care system, warning scientists that it could cause more deaths.

AstraZeneca said on Tuesday that Oxford was working with its partner to produce a vaccine tailored to Omicron, combining similar efforts with other vaccine makers.

Scientists and the government are working to strengthen their defenses against Omicron with shootings and therapies, as the threat threatens to dominate the world and has led to renewed restrictions before the holidays to contain infections.

Earlier this month, a third dose of support for the use of promoters by the UK was seen to significantly restore protection against mild illnesses caused by Omicron, with a sharp decline in vaccine effectiveness.